Functional supersensitivity of mesolimbic and striatal dopamine receptors has been suggested to contribute to the pathogenesis of schizophrenia and tardive dyskinesia. Using the rodent model of chronic administration of the neuroleptic haloperidol, we investigated the possible desensitizing effects of a tripeptide structurally unrelated to dopamine agonists, L-prolyl-L-leucyl-glycinamide (PLG) on mesolimbic and striatal dopaminergic receptor supersensitivity. Administration of PLG either prior to or after chronic haloperidol, inhibited the supersensitivity of dopamine receptors. The results have implications for pharmacological intervention in preventing tardive dyskinesia and relapse psychosis of schizophrenia.
Bibliographical noteFunding Information:
This study was supported by the Ontario Mental Health Foundation of Canada and the National Institute of Neurological and Communicative Disorders and Stroke, NIH, USA. We wish to thank Sara DeSilvio for skillfully typing the manuscript.
Copyright 2014 Elsevier B.V., All rights reserved.
- Mesolimbic and striatal dopamine receptors
- Tardive dyskinesia